Literature DB >> 11331425

Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus.

P Derkinderen1, C Ledent, M Parmentier, J A Girault.   

Abstract

Cannabinoid receptors (CB1-R) are the target of a novel class of neuromodulators, the endocannabinoids. Yet, their signalling mechanisms in adult brain are poorly understood. We report that, in rat and mouse hippocampal slices, anandamide and 2-arachidonoylglycerol, synthetic cannabinoids, and delta(9)-tetrahydrocannabinol activated p38 mitogen-activated protein kinases (MAPK), but not c-Jun N-terminal kinase (JNK). In contrast, lysophosphatidic acid (LPA), a lipid messenger acting on different receptors, increased both p38-MAPK and JNK phosphorylation. The effects of cannabinoids on p38-MAPK were mediated through activation of CB1-R because they were blocked in the presence of SR 141716 A and absent in CB1-R knockout mice, two conditions that did not alter the effects of LPA. The activation of p38-MAPK by cannabinoids was insensitive to inhibitors of SRC: These results provide new insights into the cellular mechanisms by which cannabinoids exert their effects in hippocampus.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11331425     DOI: 10.1046/j.1471-4159.2001.00333.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  41 in total

Review 1.  Microbial infections, immunomodulation, and drugs of abuse.

Authors:  Herman Friedman; Catherine Newton; Thomas W Klein
Journal:  Clin Microbiol Rev       Date:  2003-04       Impact factor: 26.132

Review 2.  Cannabinoid CB1 receptor-interacting proteins: novel targets for central nervous system drug discovery?

Authors:  Tricia H Smith; Laura J Sim-Selley; Dana E Selley
Journal:  Br J Pharmacol       Date:  2010-06       Impact factor: 8.739

Review 3.  The complications of promiscuity: endocannabinoid action and metabolism.

Authors:  S P H Alexander; D A Kendall
Journal:  Br J Pharmacol       Date:  2007-09-17       Impact factor: 8.739

4.  Extracellular signal-regulated kinase signaling in the ventral tegmental area mediates cocaine-induced synaptic plasticity and rewarding effects.

Authors:  Bin Pan; Peng Zhong; Dalong Sun; Qing-song Liu
Journal:  J Neurosci       Date:  2011-08-03       Impact factor: 6.167

5.  Behavioral and cerebellar transmission deficits in mice lacking the autism-linked gene islet brain-2.

Authors:  Joanna Giza; Michael J Urbanski; Francesca Prestori; Bhaswati Bandyopadhyay; Annie Yam; Victor Friedrich; Kevin Kelley; Egidio D'Angelo; Mitchell Goldfarb
Journal:  J Neurosci       Date:  2010-11-03       Impact factor: 6.167

6.  A synergistic interaction of 17-β-estradiol with specific cannabinoid receptor type 2 antagonist/inverse agonist on proliferation activity in primary human osteoblasts.

Authors:  Marko Hojnik; Luka Dobovišek; Željko Knez; Polonca Ferk
Journal:  Biomed Rep       Date:  2015-05-26

7.  Allosteric modulator ORG27569 induces CB1 cannabinoid receptor high affinity agonist binding state, receptor internalization, and Gi protein-independent ERK1/2 kinase activation.

Authors:  Kwang H Ahn; Mariam M Mahmoud; Debra A Kendall
Journal:  J Biol Chem       Date:  2012-02-16       Impact factor: 5.157

Review 8.  Glucocorticoids shift arachidonic acid metabolism toward endocannabinoid synthesis: a non-genomic anti-inflammatory switch.

Authors:  Renato Malcher-Lopes; Alier Franco; Jeffrey G Tasker
Journal:  Eur J Pharmacol       Date:  2008-01-31       Impact factor: 4.432

9.  The neuroprotective properties of palmitoylethanolamine against oxidative stress in a neuronal cell line.

Authors:  R Scott Duncan; Kent D Chapman; Peter Koulen
Journal:  Mol Neurodegener       Date:  2009-12-10       Impact factor: 14.195

10.  The expression level of CB1 and CB2 receptors determines their efficacy at inducing apoptosis in astrocytomas.

Authors:  Eiron Cudaback; William Marrs; Thomas Moeller; Nephi Stella
Journal:  PLoS One       Date:  2010-01-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.